organization · Reporting owner
TYNDALL CAPITAL PARTNERS L P
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Traws Pharma, Inc.
Report date September 24, 2019 · Filed September 26, 2019
Section 16 reporting ended · disclosed 2019-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 616,389 |
Reported balance
After 2019-09-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-09-24 · Sale · Disposed 16,700 · Balance 616,389 F1: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2019 Filed Sep 26, 2019 20:16 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 16,700 | $1.19 | $19,873.00 |
DisclosureSEC source: 0000905718-19-000789 · onconova_fm4sept242019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 616,389 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:08 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 37,242 | $1.23 | $45,967.80 |
DisclosureSEC source: 0000905718-19-000785 · onconova_fm4sept202019.xml · nonDerivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 633,089 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:08 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 75,119 | $1.62 | $121,429.86 |
DisclosureSEC source: 0000905718-19-000785 · onconova_fm4sept202019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 670,331 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 20:05 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 49,995 | $2.10 | $105,014.50 |
DisclosureSEC source: 0000905718-19-000781 · onconova_fm4sept182019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 745,450 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:24 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 1,247 | $2.75 | $3,432.49 |
DisclosureSEC source: 0000905718-19-000775 · onconova_fm4sept112019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 795,445 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:16 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 400 | $2.77 | $1,106.00 |
DisclosureSEC source: 0000905718-19-000773 · onconova_fm4sept092019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 796,692 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 20:10 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 5,015 | $2.78 | $13,954.24 |
DisclosureSEC source: 0000905718-19-000753 · onconova_fm4sept052019.xml · nonDerivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 797,092 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:10 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 400 | $2.75 | $1,100.00 |
DisclosureSEC source: 0000905718-19-000753 · onconova_fm4sept052019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 802,107 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 20:43 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 2,742 | $2.81 | $7,696.79 |
DisclosureSEC source: 0000905718-19-000596 · onconova_fm4jul92019.xml · nonDerivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 802,507 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 20:43 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 8,185 | $2.84 | $23,204.48 |
DisclosureSEC source: 0000905718-19-000596 · onconova_fm4jul92019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 805,249 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:35 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 1,458 | $3.45 | $5,025.00 |
DisclosureSEC source: 0000905718-19-000579 · onconova_fm4jun252019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 813,434 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:21 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 1,380 | $3.40 | $4,688.69 |
DisclosureSEC source: 0000905718-19-000557 · onconova_fm4jun252019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 814,892 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 20:12 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseSeries B Convertible Preferred Stock Purchase Warrant · Derivative | 10,147,058 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0000905718-18-000415 · onconova_fm4apr272018.xml · derivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 10,147,058 Underlying: Series B Preferred Stock · 253,677 shares Expires not disclosed F2 · derivative.exercise_price: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F2 · price: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F4 · price: 10,147,058 Units purchased for $0.425 per Unit. Each Unit consists of one share of Common Stock and one Warrant. F3 · derivative.expiration_date: The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware. F2 · derivative.underlying_shares: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F3 · derivative.underlying_shares: The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware. F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 20:12 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 10,147,058 | $0.43 | $4,312,499.65 |
DisclosureSEC source: 0000905718-18-000415 · onconova_fm4apr272018.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 12,244,080 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 00:12 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseSeries A Convertible Preferred Stock Purchase Warrant · Derivative | 1,100,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000905718-18-000125 · onconova_fm4feb82018.xml · derivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 1,100,000 Underlying: Series A Preferred Stock · 110,000 shares Expires not disclosed F2 · derivative.exercise_price: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F2 · price: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F4 · price: 1,100,000 Units purchased for $1.01 per Unit. Each Unit consists of one share of Common Stock and one Warrant. F3 · derivative.expiration_date: The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the "Charter Amendment Date") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. F2 · derivative.underlying_shares: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F3 · derivative.underlying_shares: The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the "Charter Amendment Date") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 00:12 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 1,100,000 | $1.01 | $1,111,000.00 |
DisclosureSEC source: 0000905718-18-000125 · onconova_fm4feb82018.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 2,097,022 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 22:06 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantCommon Stock | 476,190 | $2.10 | $999,999.00 |
DisclosureSEC source: 0000905718-17-000493 · tyndall_fm4apr212017.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 997,022 F1 · ownership.nature: As of April 21, 2017, Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), held 997,022 shares of common stock, par value $0.01 per share ("Shares"), and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall Capital Partners L.P. ("Tyndall Capital"), and possesses the sole power to vote and the sole power to direct the disposition of all Shares and other securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.